孟鲁司特治疗小儿哮喘的临床应用研究

目的通过孟鲁司特在小儿哮喘中的临床应用，探究其疗效。方法采用回顾分析法对本院2011年7月～2012年8月收治的采用孟鲁司特药物治疗的80例患有哮喘病小儿资料进行分析，观察其从治疗开始以后的第1、4周以及第12周的疗效，对其临床效果进行评分并通过呼气峰流速（PEF）、第1秒用力呼气容积（FEV。）的变化测定从而判断孟鲁司特在儿科哮喘治疗中的作用。结果经过临床资料证明，收治的80例患儿在接受完治疗后．病情得到了明显的改善，其中PEF、FEV1、平时临床效果的初始评分分别为108．25±18．10、72．45±2．34、5．66±0．47，在治疗周期结束后，PEF、FEV1、平时临床效果的最终评分分别为140．21±24．10、92．10±8．12、3．21±0．71．治疗前后差异具有统计学意义（P〈0．05）。结论孟鲁司特可以有效控制哮喘患儿的肺部炎症，缓解症状．改善其病情，具有良好的治疗效果，有利于患儿睡眠质量以及生活质量的提高。

Clinical application of montelukast treatment to pediatric asthma

Objective To discuss about the clinical effects of montelukast in treating pediatric asthma. Methods Eighty patients with pediatric asthma treated with montelukast in our hospital from July 2011 to August 2012 were analyzed by clinical data statistics to find the clinical results in 1, 4 weeks and 12 weeks treatment with its clinical effect scored and peak expiratory flow （PEF） and the change in first second forced expiratory volume （FEV1） tested in order to determine the effect of montelukast in pediatric asthma treatment. Results Clinical statistics proved significantly improvement of health after the treatment of the 80 patients admitted. The initial score of PEF, FEV1, clinical effect were 108.25 ± 18.10, 72.45 ± 2.34, 5.66 ± 0.47, while in the end of the treatment cycle, the final score of PEF, FEV1, clinical effect were 140.21 ±24.10, 92.10 ± 8.12, 3.21 ± 0.71, with statistically significant differences （P 〈 0.05） existed. Conclusion Montelukast can effectively control the inflammation of the lungs of patients with pediatric asthma, relive suffering and improve health condition with sound treatment effects. It will help children sleep quality as well as improve the quality of life.